TEVA Stock Recent News
TEVA LATEST HEADLINES
Teva is transforming, with management delivering on profit growth, specialty drug expansion, and improving its balance sheet—yet the stock remains undervalued. Specialty products like AUSTEDO and UZEDY are driving margin improvement, while partnerships and cost-cutting support a credible turnaround. Despite lingering legal and debt risks, Teva's low valuation offers a favorable risk/reward for patient investors willing to look past old headlines.
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Christopher J. Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Eliyahu Sharon Kalif - Executive VP & CFO Eric A.
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teva Pharmaceutical Industries reported a higher than expected rise in second-quarter profit, helped by strong sales gains of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Teva Pharmaceutical Industries Ltd. TEVA will release its second-quarter 2025 financial results tomorrow, July 30.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Teva Pharmaceutical Industries (TEVA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Though earnings season is often viewed as the highlight of each quarter, there are a number of other data releases that can tell investors a lot about the health of the stock market. In particular, the filing of Form 13F with the Securities and Exchange Commission is, arguably, one of the most important quarterly data dumps.
TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.